Actelion Ltd. Chief Executive Officer Jean-Paul Clozel has staked the future of the company he founded on an experimental drug that analysts say has a 63 percent chance of success.
Novartis AG’s troubled acquisition of Chiron Corp.’s vaccine business has one last hope -- approval of a shot to protect against a meningitis-causing bacteria.
When Pascal Soriot took the helm at AstraZeneca Plc in 2012, he inherited a company with a looming patent cliff and an ailing pipeline after a string of drug development setbacks.
Drugmakers led by Novo Nordisk A/S and Merck & Co. are increasing sales efforts for their top- selling diabetes drugs to grab as much of the market as possible ahead of a wave of new therapies.
Novartis AG plans to seek approval of a medicine for chronic heart failure sooner than expected, advancing its effort to build a portfolio of cardiac therapies.
Shire Plc became a hot property in health care by buying promising drugs, not developing them in- house. That may help AbbVie Inc. avoid the political hurdles that hurt Pfizer Inc.’s bid for AstraZeneca Plc.